Abstract: The present invention relates to a pharmaceutical composition and health functional food for preventing or treating neurodegenerative diseases which include a flower extract of Daphne genkwa or fractions thereof as an active ingredient. The pharmaceutical composition and health functional food for preventing or treating neurodegenerative diseases are, not like extracts from stems and/or roots of Daphne genkwa, free from genotoxicity and have superior prophylactic or treatment effects against neurodegenerative diseases.

Abstract: Disclosed is a battery management apparatus, which includes: a plurality of first power paths configured to electrically connect a plurality of battery modules and a balancing resistor; a plurality of first switching units configured to electrically connect or disconnect the plurality of first power paths; a plurality of second power paths configured to electrically connect the plurality of battery modules to a fan for cooling a substrate at which the balancing resistor is mounted; a plurality of second switching units configured to electrically connect or disconnect the plurality of second power paths; a residual capacity calculating unit configured to calculate a residual capacity of each of the plurality of battery modules; a determining unit configured to determine a battery module to be balanced among the plurality of battery modules based on the residual capacity; and a control unit configured to control the plurality of first switching units.

Abstract: Disclosed are a communication method between a master controller and slave controllers, a slave controller for the communication method, and a battery management system using the communication method and the slave controller, in which the master controller receives safety information about battery cells through a plurality of channels even when each of a plurality of slave controllers includes only one micro controller unit, thereby minimizing the increase in the cost and enhancing the safety of the battery management system. The communication method includes performing bidirectional communication between a master controller and first to Nth (where N is an integer equal to or more than two) slave controllers through a first communication channel, and receiving, by the master controller, an indication signal through a second communication signal via the first to Nth slave controllers.

Abstract: The present disclosure discloses a charge control apparatus and method for energy saving and high speed cell balancing. According to the present disclosure, when any one of a plurality of battery cells reaches a fully charged state, charging is temporarily stopped. Additionally, a battery cell with the lowest state of charge is determined to be a target for supplemental charging and the remaining battery cells are determined to be a target for forced discharging. Subsequently, cell balancing including supplemental charging and forced discharging is performed. When among the battery cells being forcedly discharged the number of battery cells with the same state of charge as the state of charge of the battery cell being supplementally charged is equal to or larger than a reference number, cell balancing is stopped and charging is performed again. This cell balancing process is iteratively performed each time any one of the plurality of battery cells reaches a fully charged state.

Abstract: Disclosed are a novel strain with antibacterial activity, identified as Streptomyces sp. AN1542 strain (Accession No.: KCTC 12113BP), an antibacterial composition comprising a compound represented by Chemical Formula 1 or 2, or a strain producing the same as an active ingredient, and a method for producing the same. Exhibiting potent antibacterial activity against pathogenic microbes and antibiotic-resistant microbes, particularly, MRSA, QRSA, VRSA and VRE, the compound or the strain of the present invention can be applied to the treatment of infectious diseases caused by superbacteria.

Abstract: The present invention relates to: coralmycin A and B, which are novel compounds exhibiting antimicrobial activity, an isomer thereof, a derivative thereof or a pharmaceutically acceptable salt thereof; a microorganism of the genus Corallococcus producing the same; and an antimicrobial use thereof. The coralmycin A and B have very strong antimicrobial activity against antibiotic-resistant bacteria such as MRSA, QRSA, VRE, VISA, etc.; Acinetobacter baumannii, which is a multidrug-resistant microorganism; and also against gram-positive microorganisms and gram-negative microorganisms. Therefore, the present invention can be very useful for prevention, treatment and alleviation of various microbial infections, and thus can be widely applied to the medical supply, quasi-drug, food, and feed industries.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating Parkinson's disease, which comprises, as an active ingredient, a Rhodotypos scandens extract obtained by extracting the stem of Rhodotypos scandens with an organic solvent, and a food additive showing the effect of preventing or treating Parkinson's disease, the food additive comprising Rhodotypos scandens extract as an active ingredient. The Rhodotypos scandens extracts of the present invention may prevent or treat Parkinson's disease without producing any particular side effects, and therefore can be widely used for more safely treating Parkinson's disease.

Abstract: The present invention relates to: a pharmaceutical composition or a Nurr1 activating composition for the prevention or treatment of a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the composition comprises an active ingredient in the form of genkwanin N or yuanhuacine, a Daphne genkwa extract comprising one or more of the above compounds, or a fraction thereof; or a functional food additive for preventing or alleviating a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the additive comprises genkwanin N or yuanhuacine, a Daphne genkwa extract comprising one or more of the above compounds, or a fraction thereof; and a method for the prevention or treatment of a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the method comprises the step of administering the pharmaceutical composition.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating Parkinson's disease, which comprises, as an active ingredient, a Rhodotypos scandens extract obtained by extracting the stem of Rhodotypos scandens with an organic solvent, and a food additive showing the effect of preventing or treating Parkinson's disease, the food additive comprising Rhodotypos scandens extract as an active ingredient. The Rhodotypos scandens extracts of the present invention may prevent or treat Parkinson's disease without producing any particular side effects, and therefore can be widely used for more safely treating Parkinson's disease.

Abstract: The present invention relates to: a pharmaceutical composition or a Nurr1 activating composition for the prevention or treatment of a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the composition comprises an active ingredient in the form of genkwanin N or yuanhuacine, a Daphne genkwa extract comprising one or more of the above compounds, or a fraction thereof; or a functional food additive for preventing or alleviating a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the additive comprises genkwanin N or yuanhuacine, a Daphne genkwa extract comprising one or more of the above compounds, or a fraction thereof; and a method for the prevention or treatment of a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the method comprises the step of administering the pharmaceutical composition.

Abstract: Disclosed are a novel strain with antibacterial activity, identified as Streptomyces sp. AN1542 strain (Accession No.: KCTC 12113BP), an antibacterial composition comprising a compound represented by Chemical Formula 1 or 2, or a strain producing the same as an active ingredient, and a method for producing the same. Exhibiting potent antibacterial activity against pathogenic microbes and antibiotic-resistant microbes, particularly, MRSA, QRSA, VRSA and VRE, the compound or the strain of the present invention can be applied to the treatment of infectious diseases caused by superbacteria.

Abstract: The present invention relates to an antibacterial pharmaceutical composition comprising an Aceriphyllum rossii extract, and aceriphyllic acid A and 3-oxo-12-oleanen-27-oic acid isolated therefrom. The Aceriphyllum rossii extract of the present invention, and aceriphyllic acid A and 3-oxo-12-oleanen-27-oic acid isolated therefrom have strong antibacterial activities against Staphylococcus aureus, methicillin-resistant S. aureus, quinolone-resistant S. aureus, Acinetobacter calcoaceticus, Micrococcus luteus, Bacillus subtilis or Streptococcus mutans, Propionibacterium acnes, thereby being used for the prevention or treatment of pathogenic bacterial and resistant bacterial infections, cariogenic bacterial and acne bacterial infections.

Abstract: The present invention relates to an antibacterial pharmaceutical composition comprising an Aceriphyllum rossii extract, and aceriphyllic acid A and 3-oxo-12-oleanen-27-oic acid isolated therefrom. The Aceriphyllum rossii extract of the present invention, and aceriphyllic acid A and 3-oxo-12-oleanen-27-oic acid isolated therefrom have strong antibacterial activities against Staphylococcus aureus, methicillin-resistant S. aureus, quinolone-resistant S. aureus, Acinetobacter calcoaceticus, Micrococcus luteus, Bacillus subtilis or Streptococcus mutans, Propionibacterium acnes, thereby being used for the prevention or treatment of pathogenic bacterial and resistant bacterial infections, cariogenic bacterial and acne bacterial infections.

Abstract: Plants that are substantially utilized as the medicinal ingredients in a selected single prescription of the traditional Oriental and Korean medicine are planted together in close proximity to each other. The plants provide therapeutic effects to the body of a person breathing the fragrance emitted by the plants and observing the plants. The plants are selected in accordance with the prescription of Sagunja-tang (a ginseng; a Atractylodes japonica koidz; a Glycyrrhiza uralensis Fisch; and a Pinus densiflora) or Samul-tang (an Angelica gigas Nakia; a Cnidium oficinale; a Paeonia lactiflora Pall; and a Rhemanniae glutinosa Libosch) or Palmul-tang (the eight plants selected according to Sagunja-tang and Samul-tang) or Shipjundaebo-tang (the eight plants according to Palmul-tang plus an Astrualus membranaceus Bunge var and a Cinnamon). These plants can be planted in a portable medium including at least a flowerpot.

Abstract: The present invention relates to a melanin biosynthesis inhibitor containing terrein compound as an effective ingredient. The terrein compound can be easily separated from Penicillium sp KCTC 26245, a fungal strain inhabited in domestic soil. It does not directly inhibit tyrosinase but inhibits the expression of MITF (microphthalmia-associated transcription factor) by activating ERK (extracellular signal-regulated kinase) in melanin chromatocytes to give whitening effect. So, the melanin biosynthesis inhibiting effect of the compound is much greater than that of any other conventional inhibitors, and further the effect can be raised when the compound is used together with other inhibitors, owing to their different mechanisms. Thus, the compound of the present invention can be effectively used as a skin trouble treating agent, a skin whitening agent and a browning inhibitor.

Abstract: Plants that are substantially utilized as the medicinal ingredients in a selected single prescription of the traditional Oriental and Korean medicine are planted together in close proximity to each other. The plants provide therapeutic effects to the body of a person breathing the fragrance emitted by the plants and observing the plants. The plants are selected in accordance with the prescription of Sagunja-tang (a ginseng; a Atractylodes japonica koidz; a Glycyrrhiza uralensis Fisch; and a Pinus densiflora) or Samul-tang (an Angelica gigas Nakia; a Cnidium oficinale; a Paeonia lactiflora Pall; and a Rhemanniae glutinosa Libosch) or Palmul-tang (the eight plants selected according to Sagunja-tang and Samul-tang) or Shipjundaebo-tang (the eight plants according to Palmul-tang plus an Astrualus membranaceus Bunge var and a Cinnamon). These plants can be planted in a portable medium including at least a flowerpot.